Literature DB >> 7666510

Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages.

S C Wu1, J L Spouge, S R Conley, W P Tsai, M J Merges, P L Nara.   

Abstract

Physiological microenvironments such as blood, seminal plasma, mucosal secretions, or lymphatic fluids may influence the biology of the virus-host cell and immune interactions for human immunodeficiency virus type 1 (HIV-1). Relative to media, physiological levels of human plasma were found to enhance the infectivity of HIV-1 primary isolates in both phytohemagglutinin-stimulated peripheral blood mononuclear cells and monocyte-derived macrophages. Enhancement was observed only when plasma was present during the virus-cell incubation and resulted in a 3- to 30-fold increase in virus titers in all of the four primary isolates tested. Both infectivity and virion binding experiments demonstrated a slow, time-dependent process generally requiring between 1 and 10 h. Human plasma collected in anticoagulants CPDA-1 and heparin, but not EDTA, exhibited this effect at concentrations from 90 to 40%. Furthermore, heat-inactivated plasma resulted in a loss of enhancement in peripheral blood mononuclear cells but not in monocyte-derived macrophages. Physiological concentrations of human plasma appear to recruit additional infectivity, thus increasing the infectious potential of the virus inoculum.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666510      PMCID: PMC189502     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Blocking of human immunodeficiency virus infection depends on cell density and viral stock age.

Authors:  S P Layne; M J Merges; J L Spouge; M Dembo; P L Nara
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Lipoprotein-associated oncornavirus-inactivating factor in the genus Mus: effects on murine leukemia viruses of laboratory and exotic mice.

Authors:  P L Nara; N M Dunlop; W G Robey; R Callahan; P J Fischinger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

3.  Beta 2 microglobulin enhances the infectivity of cytomegalovirus and when bound to the virus enables class I HLA molecules to be used as a virus receptor.

Authors:  J E Grundy; J A McKeating; P J Ward; A R Sanderson; P D Griffiths
Journal:  J Gen Virol       Date:  1987-03       Impact factor: 3.891

4.  Human immunodeficiency virus type 1 NL4-3 replication in four T-cell lines: rate and efficiency of entry, a major determinant of permissiveness.

Authors:  K K Srivastava; R Fernandez-Larsson; D M Zinkus; H L Robinson
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens.

Authors:  D L Mann; E Read-Connole; L O Arthur; W G Robey; P Wernet; E M Schneider; W A Blattner; M Popovic
Journal:  J Immunol       Date:  1988-08-15       Impact factor: 5.422

6.  Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. A quantitative kinetic study.

Authors:  M G Pellegrino; G Li; M J Potash; D J Volsky
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

7.  pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane.

Authors:  B S Stein; S D Gowda; J D Lifson; R C Penhallow; K G Bensch; E G Engleman
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

8.  Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.

Authors:  P Nara; L Smit; N Dunlop; W Hatch; M Merges; D Waters; J Kelliher; W Krone; J Goudsmit
Journal:  Dev Biol Stand       Date:  1990

9.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

10.  Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.

Authors:  H E Gendelman; J M Orenstein; M A Martin; C Ferrua; R Mitra; T Phipps; L A Wahl; H C Lane; A S Fauci; D S Burke
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  10 in total

1.  A practical method for simultaneously determining the effective burst sizes and cycle times of viruses.

Authors:  J L Spouge; S P Layne
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Authors:  Kenji Someya; Dayaraj Cecilia; Yasushi Ami; Tadashi Nakasone; Kazuhiro Matsuo; Sherri Burda; Hiroshi Yamamoto; Naoto Yoshino; Masahiko Kaizu; Shuji Ando; Kenji Okuda; Susan Zolla-Pazner; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  TaqMan real-time reverse transcription-PCR and JDVp26 antigen capture enzyme-linked immunosorbent assay to quantify Jembrana disease virus load during the acute phase of in vivo infection.

Authors:  Meredith Stewart; Moira Desport; Nining Hartaningsih; Graham Wilcox
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Autologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.

Authors:  D Del Mauro; D Matteucci; S Giannecchini; F Maggi; M Pistello; M Bendinelli
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure.

Authors:  Joan H Skurnick; Paul Palumbo; Anthony DeVico; Barbara L Shacklett; Fred T Valentine; Michael Merges; Roberta Kamin-Lewis; Jiri Mestecky; Thomas Denny; George K Lewis; Joan Lloyd; Robert Praschunus; Amanda Baker; Douglas F Nixon; Sharon Stranford; Robert Gallo; Sten H Vermund; Donald B Louria
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

6.  Human serum protein enhances HIV-1 replication and up-regulates the transcription factor AP-1.

Authors:  Maria F Perdomo; Waltteri Hosia; Alenka Jejcic; Garry L Corthals; Anders Vahlne
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-09       Impact factor: 11.205

7.  Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.

Authors:  L G Kostrikis; Y Cao; H Ngai; J P Moore; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Authors:  Craig Miller; Mauren Emanuelli; Elizabeth Fink; Esther Musselman; Ryan Mackie; Ryan Troyer; John Elder; Sue VandeWoude
Journal:  NPJ Vaccines       Date:  2018-04-30       Impact factor: 7.344

Review 9.  Applications of the FIV Model to Study HIV Pathogenesis.

Authors:  Craig Miller; Zaid Abdo; Aaron Ericsson; John Elder; Sue VandeWoude
Journal:  Viruses       Date:  2018-04-20       Impact factor: 5.048

Review 10.  Vaccine-induced enhancement of viral infections.

Authors:  W Huisman; B E E Martina; G F Rimmelzwaan; R A Gruters; A D M E Osterhaus
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.